ASCO: Celebrate Successes and Prepare to Support Patients in the Future

The annual scientific meeting for the American Society of Clinical Oncology (ASCO) starts this weekend in Chicago. This meeting is the premier scientific meeting for new clinical data in oncology. Reflecting on this important meeting I’m reminded of the significant advances that have been made in the last 15 years in treating cancer. Several trends fill me with hope for the future, including…

1) Increasing use of oral therapies
2) Molecularly targeted therapies offer decreased side effects versus traditional chemotherapy
3) The possibility that cancer, in many cases, can be treated as a chronic condition with an emphasis on on-going therapy

Cancer treatment is certainly much more effective, manageable, and tolerable than it was 15 years ago. While there are many advances in oncology treatment to celebrate, significant challenges remain including…  

* Patient adherence to treatment—As more oral treatments are used for treating cancer, patients and their caregivers take on a greater role for ensuring treatments are taken regularly and at prescribed doses. With treatments administered in a physician’s office or medical center the nurses see patients regularly and ensure treatments are administered as prescribed and at appropriate times. 

* Changing needs of patients and caregivers—As patients and caregivers take on more responsibility for administering treatments, they are also taking on more responsibility for monitoring and managing side effects to treatment. This can be a frightening responsibility for caregivers and more can be done to support them in this role.  

* Increased costs for treatment—On average targeted therapies cost significantly more than traditional chemotherapeutic agents. The increased cost is an issue for all stakeholders involved in oncology treatment including patients, caregivers, healthcare providers, payers, and life science companies. Patient co-pay and financial assistance programs are critical in helping many patients pay for their treatment.

For life science companies these challenges are significant, and they are also opportunities to engage with patients, caregivers, and healthcare providers. To begin, ensure you…  

* Understand the patient’s treatment journey, and in particular, the barriers they face in remaining adherent and compliant with treatment 

* Develop and implement comprehensive patient support programs that are a resource and guide for patient’s during their treatment journey  

* Inform and educate healthcare providers on the details of patient and caregiver support programs

As a pharmaceutical call center, we provide as-needed call-in support for patients, caregivers, and healthcare providers to answer questions about a product and its side effects, enroll patients in a support program, and connect patients with co-pay assistance resources. Our Medical Advisory Board works with us to design programs focused on meeting the needs of patients, caregivers, and healthcare providers.

I’d like to hear from you. What challenges does your oncology product(s) face? Please join the conversation and share your thoughts, challenges and questions.

I’ll be in Chicago at the ASCO meeting. If you’ll be at ASCO, please send me an e-mail and we’ll schedule a time to get together. I always enjoy learning about the challenges you're facing.

View Full Blog

Keep it Simple: Focus on the Patient with Adherence Programs

Hi, I'm Moriah Weissman and I'm a Clinical Director at Tunstall AMAC. I work with Lou and our life science company clients to provide clinical insights for the development of patient, caregiver, and healthcare provider support and communication programs. Lou invited me to contribute to the blog, and I look forward to sharing insights and thoughts with you, as well as learning more about your challenges.

In working with our clients there is a lot of interest in life science companies about maintaining patients on a treatment. A number of articles and studies have been published about patient adherence, and I certainly believe patient adherence can be a driver in your business. In looking at many of the patient adherence articles that have been published two thoughts come to my mind…

1. Why do most patient adherence programs seem so complicated?
2. Patient adherence programs are expensive, time-consuming, and difficult to implement!

Many of the patient adherence articles quickly become lost in the data, in analysis paralysis, or in defining whether or not a program is truly patient adherence based solely on whether or not it’s driving “behavior change”.

Perhaps I have over simplified the definition of patient adherence. To me, patient adherence is keeping a patient on a specific treatment. There are many ways this can be done, and certainly I agree that it’s important to embark on a discovery process that helps you to understand the patient journey and a patient’s desire to manage their condition. Without this it’s easy to develop a program that doesn’t drive the right actions. In fact an earlier blog post by Lou Shapiro provided suggestions for understanding the patient journey and resources for understanding a patient’s desire to manage their condition.

I believe two critical success factors for effective patient adherence programs are…

1. Develop meaningful programs that engage patients.
2. Collect feedback and data so the program can be continuously improved.

We offer four straightforward solutions to help our clients build effective patient adherence programs. These include…

1. Our focus is the patient. Start with the patient and keep them, and their needs, at the center of your solution.

2. Our AMAC Medical Advisory Board. We have relationships with healthcare providers in a number of therapeutic areas. We engage these experts to help us understand a particular disease-state/condition, current care delivery models as well as patient needs and challenges. We then work with our Medical Advisory Board to develop custom healthcare communication solutions that meet patients’ needs.

3. Our clinical program directors. They have advanced life science degrees in nursing and pharmacy. We tap into their clinical expertise to understand the patient journey and barriers to treatment as well.

4. Our pharmaceutical call center operators. They talk with healthcare providers and their offices, as well as patients and caregivers each day. They hear first-hand about the challenges patients have in managing their condition. Whether the challenges have to do with side effects, dosing, or cost, our call center operators can describe in detail what the obstacles are that patients face.

To build an effective program we take these insights and evaluate them against the product’s goals and needs. Next, we start putting together solutions that we, as a pharmaceutical call center, can provide. We also work with our clients to integrate other services, such as customized direct mail fulfillment, as appropriate.

Of course, I’ve simplified our development process for the sake of keeping this post brief. And my point is this: patient adherence programs are not rocket science. They can be straightforward and still be effective. I’m willing to bet that if you keep the patient, and their needs, at the center of your solution it will be a success.

Now, I want to hear from you. Do you agree, or do you think my oversimplified approach is wrong? Join the conversation and share your thoughts, challenges and questions.

View Full Blog  

View website for Tunstall AMAC Life Sciences